Cabaletta Bio, Inc. (CABA) stock
Close on Nov 11, 2026Market cap $245.84MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $245.84M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.87
- Dividend yield
- –
- Free cash flow yield
- -66.10%
Fundamentals
- Net income
- -$189.51M
- EPS, diluted
- -$2.10
- Free cash flow
- -$162.51M
- Book value per share
- $1.52
- Diluted shares
- 187M
Trading
- Next earnings
- Mar 22, 2027 (estimated, before the open)
- Previous close
- $1.45
- Open
- $1.46
- Day's range
- $1.38 – $1.52
- Volume
- 3,768,712
- Average volume (20 days)
- 4,755,418
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 2.86
- 52-week range
- $1.18 – $4.23
- RSI (14 days)
- 41.2
- Volatility (1 year)
- 82.9%
- Relative volume
- 0.78×
- WACC
- 17.4%
On 2 of our idea lists: Net-nets, More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CABA | S&P 500 | Difference | CABA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -24.9% | -2.4% | −22.5 pts | ||
| 3 months | -48.0% | -1.2% | −46.9 pts | ||
| Year to date | -33.8% | +12.3% | −46.1 pts | ||
| 1 year | -41.3% | +12.4% | −53.7 pts | ||
| 3 years | -91.9% | +78.8% | −170.7 pts | -56.7% | +21.4% |
| 5 years | -88.5% | +75.2% | −163.7 pts | -35.1% | +11.9% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cabaletta Bio filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Results
- Update
- Update
About Cabaletta Bio
Biological Products, (No Diagnostic Substances)
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies to provide deep, durable treatments for autoimmune conditions. Its proprietary CABA platform centers on Chimeric Antigen Receptor T cells for Autoimmunity, designed to eliminate disease-causing B cells and reset the immune system. The company's lead product candidate is rese-cel, a fully human CD19-targeting CAR T cell therapy. Its target patient populations include individuals suffering from autoimmune disorders such as dermatomyositis, anti-synthetase syndrome, systemic lupus erythematosus, lupus nephritis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
Company profile, executives and historyCabaletta Bio stock: common questions
What is Cabaletta Bio's stock price?
CABA closed at $1.45 on Nov 11, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $1.18 and $4.23.
What is Cabaletta Bio's market cap?
Cabaletta Bio was worth $245.84M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CABA's P/E ratio?
Cabaletta Bio lost money over fiscal 2025 (diluted EPS -$2.10), so it has no meaningful P/E ratio.
Does Cabaletta Bio pay a dividend?
No. Cabaletta Bio has not paid a cash dividend over the last twelve months.
When does Cabaletta Bio report earnings next?
Cabaletta Bio is expected to report Q4 FY2026 results on Mar 22, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has CABA stock performed over the past year?
Including dividends, CABA returned -41.3% over the past year, against +12.4% for the S&P 500.
How many CABA shares are sold short?
38M shares were sold short at the latest FINRA report, 23.09% of the float, or 8.2 days of average trading volume.
Who are Cabaletta Bio's competitors?
Companies most similar to Cabaletta Bio by business, industry and size include ESLA, ALLO, KYTX, CGEM, IPSC.
See a number that looks wrong?